HomeCompareREPH vs EPRT

REPH vs EPRT: Dividend Comparison 2026

REPH yields 95.69% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REPH wins by $3.20M in total portfolio value
10 years
REPH
REPH
● Live price
95.69%
Share price
$2.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.26M
Annual income
$1,067,397.24
Full REPH calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — REPH vs EPRT

📍 REPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREPHEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REPH + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REPH pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REPH
Annual income on $10K today (after 15% tax)
$8,133.97/yr
After 10yr DRIP, annual income (after tax)
$907,287.65/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, REPH beats the other by $896,373.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REPH + EPRT for your $10,000?

REPH: 50%EPRT: 50%
100% EPRT50/50100% REPH
Portfolio after 10yr
$1.66M
Annual income
$540,118.98/yr
Blended yield
32.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

REPH
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Altman Z
-1.1
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REPH buys
0
EPRT buys
0
No recent congressional trades found for REPH or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREPHEPRT
Forward yield95.69%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$3.26M$63.4K
Annual income after 10y$1,067,397.24$12,840.73
Total dividends collected$2.90M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: REPH vs EPRT ($10,000, DRIP)

YearREPH PortfolioREPH Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$20,269$9,569.38$11,205$505.18+$9.1KREPH
2$39,816$18,127.60$12,672$682.46+$27.1KREPH
3$75,882$33,279.13$14,490$930.48+$61.4KREPH
4$140,469$59,275.00$16,786$1,282.69+$123.7KREPH
5$252,850$102,548.32$19,753$1,791.56+$233.1KREPH
6$443,065$172,515.34$23,677$2,541.64+$419.4KREPH
7$756,599$282,519.41$29,008$3,672.99+$727.6KREPH
8$1,260,443$450,881.99$36,463$5,425.08+$1.22MREPH
9$2,050,673$701,999.14$47,238$8,221.57+$2.00MREPH
10$3,261,617$1,067,397.24$63,385$12,840.73+$3.20MREPH

REPH vs EPRT: Complete Analysis 2026

REPHStock

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Full REPH Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this REPH vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REPH vs SCHDREPH vs JEPIREPH vs OREPH vs KOREPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.